Earnings call transcript Q2 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Bionano's Second Quarter 2023 Earnings Conference Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to David Holmes from Investor Relations. Please go ahead.

David Holmes

Thank you, Michelle, and good afternoon everyone. second financial Bionano conference the to quarter results XXXX call. Welcome call today the is Leading Dr. of Bionano. CEO Holmlin, Erik He by is Bionano. joined Chris Stewart, of CFO

market page second issued financial Bionano can be copy closed release the release company's After its Investor website. on announcing Relations of a the results the of quarter press the found XXXX. of A for today,

and Compute, the products, certain statements benefits Saphyr driving timing System, I anticipated split and shares products, would and revenue initiatives, issuance, cost savings the of the in Bionano's these milestones, and VIA, of OGM, publications the in XXXX available commercialization of reduction forward-looking, reverse announced of and this including System impacts the of anticipated about effects of NXClinical conference anticipated improvements force, of Elevate products Bionano's advances those Software, publicly and of adoption its and Bionano's annual during authorized other anticipated associated anticipated benefits increase results benefits expectations over to outlook, like obtaining release and of for to including reimbursement in technologies, plans, XXXX, strategic recent statements anticipated Saphyr remind or advantages benefits regarding achievements from the benefits for such publications OGM. study call and made everyone of such milestones timing announced and studies quarterly and Saphyr and stock Bionano’s that and Bionano’s maybe current

no identified are as on assumes and are Bionano's and which to statements available may the with and reports contemplated Bionano's be update of can SEC. the of expectations to the such upon circumstances information to company based are change. These no obligation be assurances realized. differ in risks, based factors statements from today statements statements results number statements due forward-looking release Bionano these forward-looking filed there press materially a will current Actual results some in Such that and

and Accounting to and reconciliations financial rules GAAP, and the A at accounting non-GAAP substitute Bionano’s company expense of in conjunction considered the of reporting been press will margin reported gross Accepted An release margin, issued meant should is gross call measures Principles page. GAAP Investor both replay to or financial non-GAAP operating U.S. of GAAP Generally recording isolation end on company’s margin. comprehensive prepared operating Relations principles. measures, which Investor to be also non-GAAP company's the and today, or webcast posted operating not gross consolidated company's earlier expense statements not are audio included addition, non-GAAP non-GAAP In be for the with conference the to These website. no expense prescribed are and of and page description operating supplement comparable the with online today's for available Relations in of GAAP, in results read non-GAAP gross has GAAP prepared company's margin in by the expense accordance with on a are financial be as under or standardized meaning set GAAP have accordance non-GAAP

And Erik. to the with now that, call will I turn over

Erik Holmlin

afternoon, David, everyone. good you, Thank Great. and

well pleased report our a to on QX business as very are provide We overall. full results, the as

and cancer like Israel the the Canada. for a overall in forward or optical recent great from approval of blood in use heme malignancies Ministry for genome the support global reimbursement mapping Province on quarter research steps rise, including in optical with genome Health for of important the OGM had We've mapping second Ontario OGM

waiting and half of And these accelerants act been expected bring to the our this in the start new segment. sidelines into products, volume products second segments have customers which and like the quarter our we the believe are entry high of in will catalyze growth for will releases We've market on who had several transformational year. new as that the these product from more

we I split us the options. of This a providing Bionano's us their stock. to we extend us the this to flexibility support announced a a common choices initiative reverse initiative. I think in as process will consider to of of is financing and of we the with step more compliance with with believe make is important we aware, of it X-for-XX company's price cash believe as also thank an restore as our of requirements. investors factored listing elevating that institutional will step to more stock expenses, our runway want attractive which part this provide everybody enable stockholders This future for with was consistent we the we May management one look will and through year NASDAQ's

and performance the We the for will now of let forward move business speak itself.

our exceeded growth the same XX% business represented installed to of XXXX, the period revenue the last a over XXXX. quarter the systems For to was represents second compared increase grew guidance $X.X year. of The period quarter Saphyr which update during year-over-year XXX base million same XX and the which by for XX%

second that of There that represents quarter second increase Something year-over-year was compared out stood volume. the in the in quarter were XXXX X,XXX cells the the XXX% flow quarter XXXX. sold of consumables to and

some a particularly we that for a OGM important on medium of global developing investing two in to believe play adoption of high announced role the labs have that in and accelerating and products now. We time will run been volumes significant for in basis We samples. they

is first The Stratys.

over be to to designed as difficulty] the course powerful of and full XXXX. the first the will access Stratys XXXX Saphyr and it's in field of first an that program new ramp availability early a throughput part in increase. second Stratys times is of we released commercial scale of half system [technical of when the the expect provide to four will mapping quarter

hematologic VIA data microarray generation and data, applications. for intelligence a replaces includes product to VIA integrated application addresses bottlenecks where the and mapping, across for optical now data genome simple microarray workflow reporting next in second interpretation heme malignancies they malignancies. in NxClinical optical including and that of data genome powerful next is mapping sequencing. and generation The visualization genome variant by applications and including sequencing stands serious and workflow multiple types, optical VIA, alongside drives various which mapping

nucleic new Ionic We new System, for Purification for also released kits FFPE chemistry and extraction the tumor which from feature acid tissue.

are to samples still designed later Ionic mapping will compatible in the are kits provide these expect those on we have the for be working optical field and to developing this sequenced Now we kits genome that and year.

clinical on validating publications in optical in quarter were human for tremendous utility XX quarter applications publications clinical research. This There OGM was applications a for the of research. mapping also cytogenetics genome

manuscript optical developed are that XX% review through submitted the our genome publications and for expect up to that Overall, peer also postnatal trials year-over-year. second clinical mapping We soon. study featuring be we is constitutional published

continue the of of we open mapping big Program, growth. The announced projects and be will Bionano Duke genome which for driving optical Stanford Innovator receive areas winners part Toronto utility winners University, a Saphyr genome mapping of Hospitals for a research a and from their in optical new we Finally, optical believe Children established genome Sick which XXXX the adoption will reagents mapping. we future novel System and to three Research using University fuel and

our turn quarter call the remainder for I'd like of for over milestones Stewart, an key to the the Chris? discussing year, of CFO Chris the financials. to Before overview second

Chris Stewart

Thanks, Erik.

second quarter quarter little of million compared in margin XX% $X.X $X guidance came of XX% the numbers. million XXXX and or QX consumables. margin in instruments a gross was reflecting second in XX% million Revenue due demand non-GAAP $X.X was the an OGM to quarter stock the the Diving XX% at of compensation. $X.X the over to excludes into again deeper the to second $XXX,XXX exceeding of compared GAAP million second XX% quarter prior and XXXX quarter our non-GAAP and mainly gross margin XXXX.c increased based for quarter of gross XXXX for to XXXX increase in for of Second in

of second increase in mainly the by related product Non-GAAP XX.X expense. launches our expense second of R&D upcoming marketing was to and quarter in The to Second increases XXXX quarter $XX.X compared million was expense GAAP million operating operating driven $XX.X to million quarter headcount, expense XXXX. to the $XX.X XXXX. million compared was

save While cost second half savings XXXX. implemented $XX call, QX we into million to this including our we operating of going of half forward on in have of the to first approximately the initiatives as expenses initiatives, discussed to expect year see those reduction start headcount in our that the effect expect and we in we

related to in Second $X.X consideration and million acquisition operating expense fair Purigen. $X.X of value compensation, primarily contingent million $X.X in quarter XXXX amortization intangibles of in of increase excludes the estimated non-GAAP million our stock-based

XXXX as Our XX, available $XX.X was for million. cash, of sale cash and equivalents securities June

path a burn share, per shares of been portion is capital have cash shares our split a to best offsets $XX.X our and continue We proceeds $X.XX an and on average is QX, which per ATM In to useful $X.XX the at will raising of of it an average proactive identifying at on XX.X the basis approximately price our million adjusted runway. facility, we as million extends raised X.X be of net share. we million need. selling in price capital This

be in million million XXXX and expect the to maintaining $XX We revenue guidance to of million. are we $XX in the range our revenue QX full million $X.X $X.X year range to of

Now up. to I'll to Erik? it back turn wrap Erik

Erik Holmlin

Chris. you, Thank

to milestones validates Saphyr look XXXX. of for XXX its ahead on companies are track our pleased share XXXX. that lab require with of received for we've we second system. companies that opens CAP meet We by the control want the recently for and that strategic Bionano our goal end remain to pharmaceutical of half the this installing at Laboratories And strict level the Systems I quality outlined of door standards which quality like accreditation, collaboration to

our also track which and study, successfully. on is enrollment prenatal We of completed progressing

major and few keys product We continuing we to adoption. growth that revenue accelerating advances potentially have a believe and plan our

is which available which in of to bottleneck compatible automated a offering current with in will in select workflow. an The using isolation the significant field be customers Ionic first the will for molecular will System, clear be OGM product release weight ultra-high full and initially with DNA that XXXX isotachophoresis the protocol

It's And been an The throughput with software work second in genetic System, Compute disorders. Saphyr is that we for developed VIA collaboration throughput Stratys version analytical a NVIDIA. constitutional of high itself. to will will finally, which the flow release with is go include high

focus support mapping medical with path optical reimbursement OGM clinical clearance FDA will the of in we market advancing genome through to seeking XXXX, studies clearing in our and practice Continuing claims. clinical research and for clinical on use of changing

can we together genome succeed in on data and through further commercial controls while with for Elevate sustainable customers, Overall, we focus cost publications execution, stockholders. development our generation, growing to bringing continuing believe innovative our solutions delivering long value a analysis strategy, evidence term

With Michelle, questions. we are that, take ready to

Operator

question from [Operator Group. Instructions] Maxim come Jason first of with is line the McCarthy to Our going

Your ahead. line is open. Please go

Jason McCarthy

Hi you're cash questions. guys. expecting you the to with taking any it mention it you? be talk the a get the of gets combined right of from relatively kind you should that that runway that Thanks could measures effect quarter cash in and about a Erik, I use financial do balance aspect. the or where business saving current little and ATM or soon Can and cost bit for to want the taking a streamlining

Erik Holmlin

Jason. Thanks Yes.

we and runway. the cash and cost the company including result starting Let about the environment the will with over the ask in series bit a me certainly need runway, I'll of of I cash initiatives cash conservative. think QX, that towards in But for and on And burn, comment we that Stewart be five more expect to the of aware and programs play quarters is reductions talk focus about companies some emphasizing future shifts implemented May on cost save us those to as certainly million. and Chris markets cash a $XX overall, out QX capital savings little cash to and a

cash and strive But of basically to we but carefully opportunistic extend have the much that also financing runway non-dilutive and equity about beginning, financing possible to well. remain as as operate including much as we see a financing, options more sources as

those evaluating actively we're them. so pursuing And and

any talk QX end QX Chris the that where where million Chris? the so and takes on in activity us. let balance financing sheet of $XX I'll about of far as additional the

Chris Stewart

Yes, $XX Erik ended QX Sure. cash. said, with in as we million

is which for ATM the leverage to continue we QX, asset During us. great a

Our and money through trading volume any discount without ATM. allows raise the us to participate

well In into us shy QX we've so about know, just of And million QX far, $XX.X XXXX. raised $XX you of that runway, million. gives

- that to of is in ATM and capital terms some choosing intend - of we leveraging to us window of our we're the So that We no but ATM. need the timing raise flexibility additional raise. giving

Jason McCarthy

remains Erik, bit on track And your that commercial in you and a the at timelines it. Got how talk outlined winter. strategy little a company maybe about its committed the development Investor over could from with Day was

was it this think - I this earlier year.

Erik Holmlin

Sure. Yes, in February.

that milestones capabilities high in we've been releases and for introducing the we're that these for this optical the market quarter because are major genome Stratys were think mapping of the capacity I new announced product genome mapping which - via open for optical volume analysis. company

the key. And that's really

the highest component margin OGM of that is workflow. the think I consumable the

line it certainly beneficial, higher And supportive so run being and runway. on is cash to enable volumes of labs the able the to of financially top both

very important. were And so these announced product launches we

weight which proprietary developing, so that the the Ionic we look we'll on System. molecular through using run Looking we is ahead, technology capabilities Purigen acquired isotachophoresis, ultra-high and for the isolating is team when at

component another workflow opening greater of of OGM to volumes key for That's the up and levels utilization. higher

we building so that's running to their developing early And And reason that full end next the in we this is year they're are that commercializing optical important field towards in what expect in and menus. customer be see is year. have the could genome it something and of labs sites again, mapping for assays labs the

they so technology. to to And that it and is be capacity tools and the the we're with happy support able need increasing,

has growth to we And accelerate the even we're the milestones, capabilities are on what these the as so that we new potential these is experiencing track online. Similarly, that remain for other clinical and the really reimbursement such trials are to what's that are this barriers of down. as progressing publications publications, and these adoptions, out come really come to to wave is going make see going

Jason McCarthy

fellows. Great. Thank you,

Erik Holmlin

you, Thank Jason.

Operator

one And next for moment our you. Thank question.

from come with question Our of to Mark is going line BTIG. Massaro next the

ahead. Your line go is open. Please

Mark Massaro

Stratys to much on about you the thank strong how questions. is I love guys, ask very for the quarter. Congrats Hi a would going.

guys any believe initial any curious flow you share to of launched if near I and yet. as you I you feedback perhaps know also it? Now curious and Stratys you if have out I'm in the term rollout initiated cells full it, expect would a many, Systems soft result have how gone be Can change

Erik Holmlin

the many is expectations throughput. capable Yes. enthusiastic. very Thanks, positive. respects which expectation the Mark. response very response in And would is I to market I something, say And can was validating what higher of think - exceeding And is Stratys that that our the in our that say a it's also was seeking we that it is

this bit we doing market now end into and that XX getting through is What about XX roughly it's year are supply of around the a that the system is is reason in the initial a of which between there's constraint. period, the

So is spoken during for. we'll year up you half were all second the of be ramping the tell manufacturing can of what that, this upon announcement, almost I immediately XX and

in the problem any those to we see expect list waiting don't year having and progresses. have a as we so And come online

we're it. about enthusiastic super so And

I the point And want that demand to global. thing the is out is other

and as as So seeing in European China, North American we're the States sites, reaching sites Stratys. Canada, for well all United

repeat. the so to regard continue to flow of second a think that seeing to we far on question, that part patterns expect whether the have meaningful your we're that impact will kind cells? With I of

increase systems relatively expect And wouldn't takes getting the which a only process, I through upwards a So And few will volume. that brings and sold in accelerate a into the that system flow validation in we an the because laboratory limited play curve field. future. over to labs in expect But and in result remaining quarters capacity. quarters having yet, evaluation it's to as a its cells is higher out it few of the do next terms of the

Mark Massaro

visibility you do call is, projects? being the That's out? really growth but cell surprising. XX% and great. areas these triple quite sequential second you exceeded state question obviously any are there could Maybe digit particular used our are like is have that My what And, flow disease flow on, year-over-year, cells number to the which as expectations

Erik Holmlin

Yes.

all, this unfolds. demand lower on mapping we peaks similar. can genome optical this as strong to was peaks, So, I we've an But first to of on And outstanding be high quarter. that at that that that and be peaks generally global growth based and peaks got curve sort acknowledge validate very there lower and basis maybe to it a of or quarter and mindful a want expect continue rate

applications visibility those alternative to pharma. don't know and effects, of and what in as in know our where for to utilization, mapping of and generally to effects of regard optical editing an With integrity into we analysis cell of have XX% somewhere cells, target genome in of is but manufacturing that they're gene batches looking therapeutic are don't visibility And karyotyping therapy using target we self-therapy genome cells, perfect business XX% gene detail they're for doing. assessing off also we in around

across that look blood I in But that say of is are favor labs cancers. cytogenetics when X-to-X the would we adopting, probably utilization

leukemia, sequencing hybridization, AML, sequencing is at include ALL, events. looking labs that tell look So close And mapping fluorescence they at used ALL, the and rearrangements at these method traditional large optical sequence generation genome comes next methods us that, list use to hematologic large of but where to structural are CLL, of all lymphomas, what to arrays the these look for no variants, critical some situ in karyotyping, malignancies

prognostic subjects - optical their have put would of mapping their XX% for somewhere when of of that evaluated, genome example, in is used. so is when or labs, at score by somewhere their that to neighborhood those in around looking risk research risk research the prognostic risk XX% subjects be it they reclassified work that And they find

see why malignancies. much that's in utilization so we And hematologic so

Mark Massaro

Excellent. code with I you've if from that from MolDX. you've Last had Palmetto. since year this know Palmetto interactions CPT I'd withdrew if question a of kind an pursue Category application, X call in you had last any earlier LCD our me. curious to order be your just chance

any If or you any you 'XX just curious and have sense would thinking year timing be there. my I end have earliest, if but for maybe is updates

Erik Holmlin

Sure.

MolDX they're a that the you of with the and it's definitely multiple chip just really Palmetto in think because but role play, the working program know, of And process the I is that progressing. nationwide spear. max, kind of significant

and have later more year. with some so the discussions with we're frequently them we'll interacting formal And them in

And are types say in I projects. peg after determinations about there of it's just the expectation kind probably we're for progress now of happening that what enthusiastic aware is that prospects talking codes is getting about place, these little would CPT the say your timing want but getting we're of quite the these bit labs early is to with labs for that timeline bit in around other a line code. I X's a but reimbursement of and - also the Category going to

be than the code seek And it's a manufacturer Category lab volume's the utilization. process X to really a simpler to generally believed a for because know labs

they're optical and And being are for the see there excited remain genome mapping all about bullish so PLA reimbursed X getting. know codes covering we Category genome assays. individual CPT being And, have that that mapping. process labs And code labs progress and routinely optical we're several that continues we a to

Operator

Thank you. for question. moment one And next our

Sung line from come the Our is Ji going Nam Scotiabank. next question with of to

Your line go open. is Please ahead.

Sung Ji Nam

taking Hi, for the thanks questions.

been exposure you the of quarter. your peers two this us of those are quick to China, you Just will. and you market larger Could guys. also a housekeeping, for kind end Question you significant headwinds biopharma your again remind obviously, for kind in if have know, one

what So you. are kind you guys of seeing. just curious Thank

Erik Holmlin

it's seen think therapy impacted question. Yes, gene in by certainly that good And I certain we a and projects have down. programs cell slowing are being

they but it's exposure something you and projects, full we adoption our by year it's so say biotech have And of guidance the we limited tend these mindful see that and good to but, want I are to our optical to work that we pharma is as now anyhow. the reiterate to genome don't know, to because projects critical really for we're these mapping them. be high advance used alternative really that being doing that get needed investment what would is value a And better

So that I there. think insulation have some we

to China in And China malignancies, genetic maternal to to year was is made this the same again the in the for fertility that very optical so States, the far mapping fetal in diseases, regard genetic last United are Within made on With China, and applications of uses focus China we've year. has also progress we're diseases. strongly related that leukemias, important hematologic contributions genome and applications important namely lymphomas, of sorts medicine and applications. the seeing

are markets those And very strong.

coming headwinds China of the where services are research commercial are basic think applied that I it translational to we're are more being and in research and some of in side the more related certainly provided.

of And is us so the you. factored for million degree which and guidance reiterating this million guidance Thank full $XX that's the into put $XX that year. to for year, China strong to been that the we're out we

Operator

Thank next for question. you. our one And moment

Our from the of with Oppenheimer. next question Francois Brisebois line comes

is Your open. go line Please ahead.

Daniel Hultberg

for our Dan this This thanks Hi. and for on Congrats taking questions. on the quarter Frank. progress is

choosing the the Stratys talk there? XX about Wondering criteria in where using you're deployed. color? Any these that, what Systems Firstly, the sites could criteria early you are be would

Erik Holmlin

of basic is really And focus primary in the kind The will I them hematologic diseases and to on areas Stratys certainly think the sure. focus. and as throughput higher the selecting benefit then to that research opposed from that's malignancies sites see we like that Yes, applications. want offer genetic which Systems working

been for. has And seeing and who the and designed where so interest that's we're the demand that's the product

Daniel Hultberg

Thanks bodies strength getting you make reaching And the critical to here. publication the of regard you're With first for to one like to data across of indications, to mass feel peer reviewed guideline quick closer a me. that with do OGM conversations far, Great. that. for so start

Erik Holmlin

Yes.

what I coming published going groups groups, these statements would recommendations to existing where really writing come mean, leaders make thought international together, into we're evaluated I the will within We of begin out and consortium, to agencies call preliminary where research, start and going their see own then valuation statement. it to consensus it's their international and of and have see guidelines those groups, they're discussed own start field consensus consensus development statements are.

know I these what the is time work And coming, We making that have statements underway out say they're print, those are would efforts some been we in before that have still see but I consensus progress. and great is done.

So your point be very, good And about which together. out. lot data enabling to-date, statements their peer-reviewed progress, of is publications these a put very gotten has to

the I next of And towards synthesis we're I'm great key so unfolded. these consensus which addition think starting publication, everything step. the progress we're has with turn happy a and making to generation data that in there's statements, to and really And very is page

key there's other that already The from right? of the members involvement So have is key to these that setting consortia thing guideline come evaluate data include agencies, together agencies. these

those Having the said continue we so hematologic meet data. have it is continue we this to malignancy those in and enrollment year progress And still continue. trial, want outstanding progress that, and our that publishing and goals and will goals

Daniel Hultberg

me. the Medicare the for there. Great. dossier Thanks have you Are in the a OGM half? second final And the - expecting coverage one still for color to for submitted

Erik Holmlin

that. Mark what applications was of and coverage track part That's for Yes. around progressing local determinations and asking and work about our on we're Massaro

Daniel Hultberg

questions. again. my And taking for congrats Thanks Great.

Erik Holmlin

Thank you.

Operator

Okunewitch Instructions] next of Maxim from [Operator the question line Michael Group. you. comes with Our Thank

go open. is line ahead. Please Your

Michael Okunewitch

my quarter. for you taking and on Thank this questions Erik. the congratulations Hi, progress

Erik Holmlin

Michael. Thanks

Michael Okunewitch

Saphyr's? So appeal if to I'd appeals because customers. avoided this who the I start to meet like to Or have terms the you a in throughput. nature customers use of anticipate and Dan's to follow-up expecting needs guess, Stratys [technical already off, Are doesn't of question just little could you difficulty] but you to see it that OGM, would OGM, on, Saphyr Stratys their bit talk about

Erik Holmlin

a users in system evaluation expect I to higher to that's the higher want to be to emphasize and a several volumes available use I for continue who, and have Stratys kind on-site. get of that and their but represent of by OGM do do level, the medium kind some they platform yes Saphyr I will cases kind really think workflows can really So volume outstanding transform to it's just fold. of key already field a volume and like bring the Saphyr, a really yes, sites low intend but increases there the be entry incredible for as in do capabilities and results

what so are running coming samples that of of on that raising utilization the OGM. their want I And are and already the of And see - that's labs year. driving to of we that we literally per is kind really that are board thousands labs think hand and that's kind adoption see business

simply installed be that practical it And wouldn't really have to many Saphyr Systems in a lab.

something the and community. data the it's progress, the out way our to and be Stratys who have offer the that's volume. playing have able around the to field bringing higher And saying, only that's propositions well, and all we following proof is for that advancement bridging gap been value to these folks that is So do in to the want in

principal really who that's so that's, target. see course, we system on of And And board. our the bringing

Michael Okunewitch

targeting? on you order that. to for Thank status in right. need follow-up you're And like I'd All bring that rate data you what to that thirteenfold to just to generation steps really take

Erik Holmlin

to system, Ionic, the with right? the least going there, of data is So, DNA get which other is And what workflow going ITP able ways, fourfold to increase it's a but in on bottleneck to the Stratys, automate in is about they're system sort of it in modular, sort about adopt are adopts the Saphyr that throughput throughput. there get a somebody So Well, Well, which at trade-off to over delivers. to fourfold a will customers isolation? increase between we're the and what a be it's Stratys, Is which generation right? platform their degree bottleneck?

number And modularly them on their systems robotic what's of to instruments development on the multiple really and the you to is that, to systems instrument. do And link leverage not increase we collective allow really that system our operate so the together is about mechanical that throughput. need exciting have capabilities working increases is the that strategy that in

instrument with bringing sure done I'm down We've is we'll over time. upgrade developed. drive So the manufacturing the throughput in new components Saphyr enhance And over by costs components continue that to time. to to

don't achieve a integrating real lot a of levels we systems to higher together throughput. robotic mechanical It's mechanical have required But systems. multiple of using process really invention of these

being as genome relatively the And of so mapping that optical to we enable see risk for utilization. low growth continuing and critical

Michael Okunewitch

me, All One different if you the bit of I'd to about I'll complexity more - I applications. see little a just for right. applying like could talk VIA and back the into to Thank you. queue. hop

As in does something about teams for VIA talking the workflow differ versus when software? disease a like how genetic -

Erik Holmlin

level, and is be It's single through only can it up. rearrangements that is way all sequence it genome analysis powerful mapping extends really I large to so some that a question. And up detected reliable that very think be at what's Yes. - and applied the picking nucleotide optical structural would variants any of NGS variant in good any and by chromosomal from at VIA generic genome that about exciting variants, variants is

it these why that And interpretation. comes specific? or into That releases the application is so

a variant, detect do you if So you with do what it?

and that's allows publication you different knowledge particular fashion, databases, query forth. VIA interpretation. your applications allows data variant available you the so automated to accelerate an in on in intelligence databases really And bases, that through that available its to

process - that first what hematologic is we're So for optimized that we malignancies, what we now did and genetic for we're constitutional disorders. doing doing really

with that discovery something that long for know, would for comes are and illustrates because when don't of sequence been say familiar it variation you has about not around kind to analysis robust sequencing process people really, variant this And time. I a structural

Next and for generation been well has sequencing decade out available over a now.

nearly so not databases. around easy sequence comes to the structural calls And are variant query far are well in it's to databases databases as But the populated it variants, along. variants when and these

and development some requires it so customization. And

Network, a in piece workloads. incredibly it will critical that capability such provides gate, frameworks it's World right these that now as VIA. malignancy and And integrate researchers for reports that And really use those out to are into the guidelines evaluate needed other are their will validated way to and laboratories others. specific samples the hematologic National VIA that's of The done out so reporting. sort Organization But the those customizable into we Health the Cancer to of is integrate that is Comprehensive there that

and And laboratories similarly, constitutional are unique around own disorders what reporting genetic has to its accustomed delivering. nuances

when so comes is and some it And application interpretation customization reporting. to there

Michael Okunewitch

Thank right. All much. very you

Operator

Erik I'm And any time. hand at And further no further over Holmlin conference I'd for the like back you. Thank to questions remarks. this showing to

Erik Holmlin

genome which And And our I we Bionano Thank on call, QX optical forward to and for And the look mapping. you want soon. you, upcoming everybody tremendously Michelle. will thank joining to want about be future of we I today. are to excited emphasize that updating

So thank you shortly. to and speak you

Operator

This does Thank today's program. conclude for you participating.

You may now disconnect.

Bionano Genomics (BNGO) 9 Aug 232023 Q2 Earnings call transcript